Page last updated: 2024-11-10

vitexin rhamnoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2''-O-rhamnopyranosylvitexin: has both analgesic and anti-inflammatory activities; isolated from Alternanthera maritima; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

vitexin 2''-O-alpha-L-rhamnoside : A derivative of vitexin having an alpha-L-rhamnosyl residue attached at the 2''-position of the glucitol moiety. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

vitexin rhamnoside: an apigenin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5282151
CHEMBL ID1685070
CHEBI ID32298
SCHEMBL ID1954688
MeSH IDM0076040
PubMed CID5488886
CHEMBL ID1685071
CHEBI ID189451
MeSH IDM0076040

Synonyms (52)

Synonym
ACON1_001257
MEGXP0_001018
2''-o-rhamnosylvitexin
vitexin 2''-rhamnoside
64820-99-1
NCGC00169526-01
apigenin-8-c-glucoside-2'-rhamnoside
CHEBI:32298 ,
vitexin 2''-o-alpha-l-rhamnoside
(1s)-1,5-anhydro-2-o-(6-deoxy-alpha-l-mannopyranosyl)-1-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-chromen-8-yl]-d-glucitol
vitexin-2''-rhamnoside
(1s)-1,5-anhydro-2-o-(alpha-l-rhamnopyranosyl)-1-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-chromen-8-yl]-d-glucitol
2-o-rhamnosylvitexin
BRD-K00786504-001-01-8
vitexin 2''-o-rhamnoside
CHEMBL1685070
unii-ud7y63i5x5
ud7y63i5x5 ,
8-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
vitexin-2-o-rhamnoside
vitexin-2''-o-rhamnoside
8-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-tetrahydropyran-2-yl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
vitexin 2-o-rhamnoside
AKOS015897136
S5460
SCHEMBL1954688
rhamnosylvitexin
2''-o-rhamnopyranosylvitexin
2''-rhamnosylvitexin
DTXSID20215119
vitexin 2-o-rhamnoside, primary pharmaceutical reference standard
vitexin 2-o-rhamnoside, analytical standard
AS-57695
8-((2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)tetrahydro-2h-pyran-2-yl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4h-chromen-4-one
Q27114859
HY-N0534
CS-0009067
CCG-270120
vitexin-2'-o-rhamnoside
vitexin-2invertedexclamationmarka-o-rhamnoside
GLXC-13461
vitexin-2''-o-rhamnoside (constituent of hawthorn leaf with flower)
vitexin rhamnoside
32426-34-9
5,7-dihydroxy-8-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-[4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyphenyl]chromen-4-one
CHEBI:189451
vitexin-4'-rhamnoside
CHEMBL1685071
einecs 251-036-0
8-glycosyl-apigenin-rhamnoside
2-(4-((6-deoxy-alpha-l-mannopyranosyl)oxy)phenyl)-8-beta-d-glucopyranosyl-5,7-dihydroxy-4h-benzopyran-4-one
DTXSID00186171

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" After intravenous administration of HLF to rats over the doses range of 10-40 mg/kg, the plasma concentration--time curves of VGL and VRH were both conformed to the three-compartment open pharmacokinetic model and linear pharmacokinetic characteristics."( Simultaneous determination of vitexin-4''-O-glucoside and vitexin-2''-O-rhamnoside from Hawthorn leaves flavonoids in rat plasma by HPLC method and its application to pharmacokinetic studies.
Chen, Z; Jiang, XH; Li, CR; Liu, TM; Ma, G; Ren, J, 2007
)
0.34
"A simple and specific high-performance liquid chromatographic (HPLC) method was developed for the pharmacokinetic study of vitexin-2''-O-rhamnoside (VOR) in rat after intravenous administration."( High-performance liquid chromatographic determination and pharmacokinetic study of vitexin-2''-O-rhamnoside in rat plasma after intravenous administration.
Bi, Y; Gao, S; Li, F; Li, X; Qin, F; Ying, X; Zhu, W, 2007
)
0.34
" The main pharmacokinetic parameters were estimated by pharmacokinetic program 3p87."( [Determination of vitexin-rhamnoside in Beagle dog plasma and preliminary pharmacokinetics of Yixintong sustained release tablets].
Feng, NP; Li, SM; Qu, L; Zheng, HS, 2008
)
0.35
"The pharmacokinetic profiles of Yixintong sustained release tablets and the general tablets were fitted to a one-and two-compartment open model, respectively."( [Determination of vitexin-rhamnoside in Beagle dog plasma and preliminary pharmacokinetics of Yixintong sustained release tablets].
Feng, NP; Li, SM; Qu, L; Zheng, HS, 2008
)
0.35
"The sustained-release characteristic of Yixintong sustained release tablets were confirmed by pharmacokinetic study."( [Determination of vitexin-rhamnoside in Beagle dog plasma and preliminary pharmacokinetics of Yixintong sustained release tablets].
Feng, NP; Li, SM; Qu, L; Zheng, HS, 2008
)
0.35
" The validated method was suitable to the pharmacokinetic study of HP, FA and CA in rats after oral administration at a single dose of POE."( LC determination and pharmacokinetic study of the main phenolic components of Portulaca oleracea L. extract in rat plasma after oral administration.
Cheng, Z; Du, Y; Kang, T; Wang, D; Wang, Y; Ying, X; Zhai, Y; Zhang, W, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" To investigate their bioavailability in in vivo animal studies an enzyme-linked immunosorbent assay (ELISA) method has been developed."( An enzyme-linked immunosorbent assay for the measurement of plasma flavonoids in mice fed apigenin-C-glycoside.
Angelino, D; Buondelmonte, C; Dominici, S; Gennari, L; Giorgi, L; Ninfali, P, 2013
)
0.39
" The assay represents a useful tool for rapid screening to compare bioavailability of apigenin flavonoids in respect to control animals."( An enzyme-linked immunosorbent assay for the measurement of plasma flavonoids in mice fed apigenin-C-glycoside.
Angelino, D; Buondelmonte, C; Dominici, S; Gennari, L; Giorgi, L; Ninfali, P, 2013
)
0.39
"To develop an HPLC method to determine vitexin-rhamnoside in plasma of Beagle dogs and study the pharmacokinetics and bioavailability of Yixintong sustained release tablets in Beagle dogs."( [Determination of vitexin-rhamnoside in Beagle dog plasma and preliminary pharmacokinetics of Yixintong sustained release tablets].
Feng, NP; Li, SM; Qu, L; Zheng, HS, 2008
)
0.35
" The relative bioavailability of the Yixintong sustained release tablets was 115."( [Determination of vitexin-rhamnoside in Beagle dog plasma and preliminary pharmacokinetics of Yixintong sustained release tablets].
Feng, NP; Li, SM; Qu, L; Zheng, HS, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
" The association of the seven extracts seemed to act in a synergetic way, the resulting activity being sedative at high dosage and anxiolytic at low dosage."( [Evaluation of the activity on the mouse CNS of several plant extracts and a combination of them].
Della Loggia, R; Redaelli, C; Tubaro, A,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
C-glycosyl compoundA glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a carbon atom, thus creating a C-C bond.
trihydroxyflavoneAny hydroxyflavone carrying three hydroxy groups at unspecified positions.
disaccharide derivativeA carbohydrate derivative that is formally obtained from a disaccharide.
flavonoidsAny organic molecular entity whose stucture is based on derivatives of a phenyl-substituted 1-phenylpropane possessing a C15 or C16 skeleton, or such a structure which is condensed with a C6-C3 lignan precursors. The term is a 'superclass' comprising all members of the classes of flavonoid, isoflavonoid, neoflavonoid, chalcones, dihydrochalcones, aurones, pterocarpan, coumestans, rotenoid, flavonolignan, homoflavonoid and flavonoid oligomers. Originally restricted to natural products, the term is also applied to synthetic compounds related to them.
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID578759Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1764181Hypolipidemic activity against oleic acid/palmitic acid-induced hyperlipidemia in human HepG2 cells assessed as reduction in triglycerides content2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Phenolic compounds from the leaves of Crataegus pinnatifida Bge. var. major N.E.Br. And their lipid-lowering effects.
AID578765Inhibition of P-gp expressed in A2780adr cells at 10 uM by calcein AM accumulation assay relative to verapamil2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID578843Cytotoxicity against human A2780 cells assessed as intracellular ATP level at 10 uM after 72 hrs by luminometry2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID578844Cytotoxicity against human MCF7 cells assessed as intracellular ATP level at 10 uM after 72 hrs by luminometry2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID578760Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID578843Cytotoxicity against human A2780 cells assessed as intracellular ATP level at 10 uM after 72 hrs by luminometry2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID578760Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID578765Inhibition of P-gp expressed in A2780adr cells at 10 uM by calcein AM accumulation assay relative to verapamil2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID578759Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID578844Cytotoxicity against human MCF7 cells assessed as intracellular ATP level at 10 uM after 72 hrs by luminometry2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.03)18.7374
1990's1 (3.03)18.2507
2000's10 (30.30)29.6817
2010's18 (54.55)24.3611
2020's3 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.19 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index34.32 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Reviews2 (6.90%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
Other27 (93.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]